MEA Liver Disease Treatment Market

MEA Liver Disease Treatment Market Size (2022 to 2027)

The size of the Liver Disease Treatment Market in the Middle-East & Africa is expected to reach USD 5.59 billion by 2027 from USD 3.19 billion in 2027, growing at a CAGR of 11.89% during the forecast period.

The increasing incidence of liver infections and diseases is majorly driving the liver disease treatment market in MEA. In addition, the growing population and the associated lifestyles such as unhealthy diets, excessive drinking of alcohol are fuelling the market growth.  The ever-increasing geriatric population significantly influences the liver disease treatment market, as the senior population is prone to liver infections and various diseases. In addition, there has been a significant demand for this market in the recent past due to illnesses that have become common in middle east Africa. 

Increasing investments by the government to create awareness among the people about the prevalence of cancer and availability of advanced treatments in the market through medical tourism and healthcare programs are projected to influence market growth positively.

One of the causes of fatty liver disease is overeating or obesity. Fatty liver disease is caused by the accumulation of too much fat in the liver. Obesity has been increasingly prevalent in recent years, with a significant increase in the number of persons affected. According to the World Health Organization, alcohol-related liver diseases and the obese population are on the rise, and these are the primary drivers of the liver disease treatment market.

The increase in population is also causing these liver disorders, owing to the increasing consumption of alcohol leading to liver cancer and liver cirrhosis. Therefore, key market players and governments are significantly investing in research and development activities which are expected to provide lucrative growth opportunities to the market growth. 

However, strict government rules in the production of drugs, limited investments, complicated procedures in getting drug approval, and the high cost of drug manufacturing is majorly impeding the market growth. On the other hand, the side effects of the drugs and heavy competition from natural medicine further limit the market growth.  

This research report on the MEA liver disease treatment market has been segmented and sub-segmented into the following categories:

By Treatment Modality:

• Antiviral
• Vaccines
• Chemotherapy
• Immunosuppressive Agents
• Corticosteroids

By Disease Type:

• Hepatitis
• Non-Alcoholic Fatty Liver Disease
• Alcohol-Induced
• Liver Cancer

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the MEA is anticipated to account for a moderate share in the global liver disease treatment market during the forecast period. The improving healthcare sector, high prevalence of liver diseases, and presence of key market players are propelling the market growth. In addition, emerging countries such South Africa, UAE, and Saudi Arabia are significantly expanding the MEA regional market.

South Africa accounted for the largest share of the market, and it is more likely to continue its growth during the forecast period. Liver disease has been the major problem in the country; several death cases are recorded due to the high prevalence. In addition, the growing awareness about liver diseases, increasing healthcare spending, and improving healthcare infrastructure.

On the other hand, other countries such as Saudi Arabia and UAE are projected to showcase a promising share during the forecast period. Increasing consumption of alcohol, growing population, and the associated lifestyles are boosting the market growth. In addition, the growing obese population is contributing to the market growth in these countries.

KEY MARKET PLAYERS:

Companies playing a leading role in the MEA liver disease treatment market profiled in the report are Gilead Science Inc. (U.S.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Johnson & Johnson (U.S.), Novartis (Switzerland), Roche (Switzerland), Sanofi-Aventis (France), Abbott Laboratories (U.S.), Bayer Schering AG (Germany) and AstraZeneca (United Kingdom).